scholarly journals Spectroscopic Studies of in Vitro Exposure to Low-Dose Gamma Rays from 137Cs Radioactivity on Some Human Blood Components (Plasma and Red Blood Cells)

Author(s):  
Benjamaporn Supawat ◽  
Watcharit Vorasiripreecha ◽  
Sakornniya Wattanapongpitak ◽  
Suchart Kothan ◽  
Montree Tungjai

Abstract This current study was to determine the effects of in vitro exposure to radioactive cesium-137 on some human blood components (Plasma and red blood cells). Blood samples were given a radiation dose of 0.02, 0.05, 0.1, 0.2, and 0.3 mGy of gamma rays using a 137Cs radioactive standard source. The blood samples that were exposed to 0 mGy served as sham-controls. The spectrofluoroscopic technique was used to determine the autofluorescence spectrum of protein in plasma or red blood cells by using excitation wavelength and range of emission wavelengths at 280 nm and 300-550 nm, respectively. The spectrophotometric technique was used to determine the release of hemoglobin from the red blood cells to the supernatant. This data indicated no change in the ratio of fluorescence emission intensity at 340 nm of wavelength of protein extract from irradiated whole blood or red blood cells compared to the corresponding non-irradiated control. The results did not change in the absorption intensity at 415 nm of wavelength of hemoglobin leakage from in vitro irradiated red blood cells when compared to the corresponding non-irradiated red blood cells. These current results suggested that there were no harmful effects of the low-dose gamma rays from radioactive 137Cs on some blood components when human whole blood was exposed to gamma rays in an in vitro condition.

1958 ◽  
Vol 193 (2) ◽  
pp. 244-248 ◽  
Author(s):  
Perry Ruth Stahl ◽  
Homer E. Dale

In a repeated study on 17 dairy calves, T-1824 dye plasma dilution showed significantly higher blood volumes than were found by any other technique or computation method using Cr51-tagged red blood cells. Five blood samples taken at 20-minute intervals after injection showed consistent decrease in radioactivity count from the first to the last sample, indicating greater accuracy in radioactivity dilution regressed to zero time figures than in average counts of several postinjection samples. In vitro studies suggest a loss of Cr51 from red blood cells to plasma after saline washings are Cr-free. Percentage blood volumes computed from whole blood samples of calves injected with Cr51-tagged red blood cells decreased in a straight line relationship with increase of body weight. Percentage plasma and whole blood volumes estimated with the T-1824 dye technique decreased regularly with body weight increase until a second determination was made when there was a rapid rise nearly to the level of the smallest calves, followed by another regular decrease with increase in weight. It is suggested that repeated dye injections do not always measure the same space. Regressed values of five whole blood samples taken at 20-minute intervals after injection of Cr51 tagged red blood cells gave more consistent blood volume determinations than either the weighed red cells or the plasma dye dilutions of the same samples.


Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Seán Fitzgerald ◽  
Daying Dai ◽  
Andrew S Douglas ◽  
Oana M Mereuta ◽  
Thomas Caracena ◽  
...  

Introduction: Previous studies have successfully created blood clot analogues for In-vitro testing using animal blood. Blood components vary greatly among species and thus, creating clot analogues with human blood is likely a more accurate representation of thrombi formed in the human vasculature. We present a novel method of creating clot analogues from human blood and platelets that mimic the process by which clots form In-vivo . Methods: Following IRB approval from Mayo Clinic, human whole blood and platelets donations were obtained from the Blood Transfusion service. The whole blood was centrifuged at 1,200RPM for 20 minutes to separate it into its constituents. Plasma was removed and the remaining Red Blood Cells and Buffy Coat were mixed together by inverting. A total of 12 clot analogues were created with varying concentrations of components; Red Blood cells/Buffy Coat, Plasma and Platelets. Thrombin was added first to stimulate platelets activation for a total of 5 mins whilst continuously mixing by inversion. The RBC/WBC mixture was added next followed by CaCl2. The mixture was then quickly drawn into a 3cc syringe and spun overnight at 20RPM at room temperature to mimic dynamic flow conditions. Macro-photographs were taken to display the variation in texture and color between different clot analogue types. The clots were then fixed in 10% neutral buffered formalin for 24 hours prior to being processed. Histopathological analysis was performed using Hematoxylin and Eosin (H&E) and Martius Scarlet Blue (MSB) staining to confirm clot composition. Results: Red Blood cell-rich, Fibrin-rich, Platelet-rich and mixed clot analogues that accurately mimic clots retrieved from Acute Ischemic Stroke Patients were created. The range of histopathological compositions of the clot analogues is similar to that of the clinical samples. Conclusions: The addition and activation of platelets is key to creating accurate clot analogues for In-vitro testing. Spinning the clots is important to prevent natural sedimentation and mimic the In-vivo situation.


2010 ◽  
Vol 53 (3) ◽  
pp. 575-582 ◽  
Author(s):  
Jacques Natan Grinapel Frydman ◽  
Adenilson de Souza da Fonseca ◽  
Vanessa Câmara da Rocha ◽  
Monica Oliveira Benarroz ◽  
Gabrielle de Souza Rocha ◽  
...  

This work evaluated the effect of in vitro and in vivo treatment with ASA on the morphology of the red blood cells. Blood samples or Wistar rats were treated with ASA for one hour. Blood samples or animals treated with saline were used as control group. Blood smears were prepared, fixed, stained and the qualitative and quantitative morphology of red blood cells were evaluated under optical microscopy. Data showed that the in vitro treatment for one hour with ASA at higher dose used significantly (p<0.05) modified the perimeter/area ratio of the red blood cells. No morphological alterations were obtained with the in vivo treatment. ASA use at highest doses could interfere on shape of red blood cells.


2019 ◽  
Vol 11 (3) ◽  
pp. 237-243 ◽  
Author(s):  
Montree Tungjai ◽  
Jetchada Sopapang ◽  
Natdanai Tasri ◽  
Chanatip Osothsongkroh ◽  
Attapon Jantarato ◽  
...  

Biologicals ◽  
2010 ◽  
Vol 38 (1) ◽  
pp. 14-19 ◽  
Author(s):  
N.A. Mufti ◽  
A.C. Erickson ◽  
A.K. North ◽  
D. Hanson ◽  
L. Sawyer ◽  
...  

Vox Sanguinis ◽  
1957 ◽  
Vol 2 (2) ◽  
pp. 104-109 ◽  
Author(s):  
S. ROTHMAN ◽  
E. ADELSON ◽  
A. SCHWEBEL ◽  
R. D. LANGDELL

2016 ◽  
Vol 49 (7) ◽  
pp. 1021-1026 ◽  
Author(s):  
K. Lee ◽  
M. Kinnunen ◽  
A.V. Danilina ◽  
V.D. Ustinov ◽  
S. Shin ◽  
...  

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 986-986
Author(s):  
Alison Leigh Banka ◽  
Mark Shamoun ◽  
Mario Gutierrez ◽  
Tyler Tanski ◽  
Lola Eniola-Adefeso

Introduction: Sickle cell disease (SCD) occurs due to a mutation in the β-subunit of hemoglobin, causing stiffening of red blood cells (RBCs) and leading to RBC sickling and vaso-occlusive crises (VOC) in SCD patients. While sickled RBCs remain a hallmark of SCD, they are prone to lysis and represent a small fraction of the total RBCs present in patients at a given time. The remaining RBCs maintain a normal, discoid shape and are either healthy or stiff due to polymerization of the hemoglobin β-globin subunit. In healthy blood flow, RBCs form a core in the center of the vessel and the remaining cells, platelets and white blood cells (WBCs), marginate towards the endothelium. However, the increased stiffness of RBCs in SCD disrupts this neat segregation of blood cells to different areas of the blood vessel and can contribute to VOC, the root cause of many acute and chronic complications for SCD patients. Despite the presence of normally shaped, stiffened RBCs in SCD patients, the impact of these RBCs on other cell types in blood flow is currently not well understood. Our laboratory previously demonstrated that the presence of artificially rigidified RBCs leads to an expansion of the RBC core and significantly decreases WBC adhesion to an inflamed endothelium in vitro. Here, we examine the impact of stiffened RBCs on platelet adhesion to a damaged endothelium in vitro by first using a model system with artificially rigidified RBCs and second, utilizing SCD patient blood to further support our model and understand platelet-RBC interactions in SCD patients. Methods: In our model system, we artificially rigidified RBCs taken from healthy donors and reconstituted them into whole blood before perfusing the mixture over an activated, damaged endothelium using a parallel plate flow chamber. We quantified platelet adhesion to the endothelium in comparison to healthy, non-rigidified controls using fluorescent microscopy. To determine if our model findings translated to SCD, we recruited a cohort of hemoglobin SS and SC patients during routine visits and similarly perfused their whole blood over the same damaged endothelium and quantified platelet adhesion. Results and conclusions: The inclusion of artificially rigidified RBCs in otherwise healthy subject blood flow significantly increased platelet adhesion to a damaged endothelium with a maximum increase in platelet adhesion of six-fold over a healthy, non-rigid control in our model system. Both RBC rigidity and the percentage of RBCs that were artificially rigidified had a large impact on the increase in platelet adhesion. SCD platelet adhesion to the damaged endothelium model varied from donor to donor based on variables such as treatment method and disease severity. Overall, this work experimentally elucidates the biophysical impact of stiffened RBCs on platelet adhesion using both an artificial model utilizing healthy blood as well as SCD blood, which can help determine the mechanism of action causing VOC in SCD. Disclosures No relevant conflicts of interest to declare.


Transfusion ◽  
2019 ◽  
Vol 59 (10) ◽  
pp. 3197-3204
Author(s):  
Peter Schubert ◽  
Brankica Culibrk ◽  
Deborah Chen ◽  
Katherine Serrano ◽  
Elena Levin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document